FDA Determines Regulatory Review Period for OPDIVO Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for OPDIVO, a human biological product, as required by law after receiving a patent extension application from the U.S. Patent and Trademark Office (USPTO).